Tuning Reactivity of Platinum(II) Complexes
Tuning Reactivity of Platinum(II) Complexes Tuning Reactivity of Platinum(II) Complexes
Table of Contents-1 Chapter 1 .................................................................................................................................................................. 1 1.0 Introduction ...................................................................................................................................................... 1 1.1 Cancer disease ............................................................................................................................................. 1 1.2 Cancer Treatment ...................................................................................................................................... 1 1.2.1 Chemotherapy ......................................................................................................................................... 2 1.3 Platinum chemistry .................................................................................................................................. 2 1.3.1 Platinum-Based Anticancer Drugs ................................................................................................ 3 1.3.2 Cisplatin ...................................................................................................................................................... 4 1.3.2.1 Mechanism of Action ........................................................................................................................ 4 1.3.2.2 Cellular Uptake .................................................................................................................................... 5 1.3.2.3 Hydrolysis .............................................................................................................................................. 5 1.3.2.4 DNA adducts and Cell Response ................................................................................................. 6 1.3.2.5 Cisplatin Resistance .......................................................................................................................... 8 1.3.2.6 Competition between N– and S–Donor Nucleophiles ...................................................... 8 1.3.3 New and “Non-classical” platinum complexes ..................................................................... 10 1.3.3.1 Second generation Cisplatin Analogues ............................................................................... 10 1.3.3.2 Platinum(IV) complexes .............................................................................................................. 12 1.3.4 Terpyridine platinum(II) complexes ......................................................................................... 13 1.3.5. Multinuclear Platinum(II) complexes ...................................................................................... 14 1.3.5.1 Amino Linkers .................................................................................................................................. 15 1.3.5.2 Aromatic linkers .............................................................................................................................. 16 1.4 Kinetic Interest ........................................................................................................................................ 17 1.5 Aim and Scope of this Study .............................................................................................................. 17 References .............................................................................................................................................................. 20 List of Figures Figure 1.1: Classification of chemotherapy drugs................................................................................ 2 Figure 1.2: Chemical structures of selected platinum compounds ........................................................ 4 Figure 1.3: Intracellular hydrolysis and bio-activation of cisplatin in aqueous solution leading to binding at DNA in the cell nucleus. ........................................................................................................ 6 i
Figure 1.4: DNA-adduct formation with cisplatin leaving two amino groups coordinated on the platinum atom. The main adducts formed in the interaction cisplatin with DNA: (a) interstrand crosslink; (b) 1,2-intrastrand cross-link; (c) 1,3-intrastrand cross-link and; (d) protein-DNA cross-link. ..... 7 Figure 1.5: Schematic pathway of a platinum drug in cells showing how sulphur containing compounds are thought to act as potential drug reserving agents in platinum chemotherapy. ............... 9 Figure 1.6: DNA adducts formed by oxaliplatin 13 . ............................................................................... 11 Figure 1.7: Structure of a sterically hindered platinum(II) complex (ZD0473) that circumvents cisplatin resistance. ............................................................................................................................. 12 Figure 1.8: Selected Pt(II) metallo-intercalators: terpy = terpyridine, phen = phenanthroline, 4picoline = 4-methylpyridine, en = 1,2-diaminoethane, and HET = 2-hydroxyethanethiolato ligand. ................................................................................................................................................... 13 Figure 1.9: Selected Multinuclear platinum(II) complexes with flexible amino- and rigid azine and azoles ligands. , .............................................................................................................................. 15 Figure 1.10: Structure of extended terpy Pt(II) complexes; blue ring for isoquinoline ring and red for phenanthroline ring system. .................................................................................................. 18 ii
- Page 1 and 2: Tuning Reactivity of Platinum(II) C
- Page 3 and 4: Declaration This thesis report is b
- Page 5 and 6: Abstract Systematic kinetic and the
- Page 7 and 8: Table of contents Acknowledgements
- Page 9 and 10: 2.5.5 Effect of Non-participating G
- Page 11 and 12: 5.2.1 Chemical and Solutions ......
- Page 13 and 14: 7.2 Experimental Section ..........
- Page 15 and 16: procurements, Messers P. Forder and
- Page 17 and 18: Figure 2.2 Potential energy profile
- Page 19 and 20: Figure 4.6 Concentration dependence
- Page 21 and 22: Figure 6.1 Spectrophotometric titra
- Page 23 and 24: List of Tables Table 2.1 A selectio
- Page 25 and 26: Table 6.4 Summary of rate constants
- Page 27 and 28: TU thiourea DMTU 1,3-dimethyl-2-thi
- Page 32 and 33: 1.0 Introduction 1.1 Cancer Disease
- Page 34 and 35: toxic potential. The most well-know
- Page 36 and 37: 1.3.2.2 Cellular Uptake Cisplatin i
- Page 38 and 39: H 3N OH 2 Pt H 3N OH 2 Active Pt(II
- Page 40 and 41: transformational pathways that comp
- Page 42 and 43: the hydrolysis of the complex, wher
- Page 44 and 45: 1.3.4 Terpyridine Platinum(II) Comp
- Page 46 and 47: H 3 N Cl Pt NH 3 H 3 N NH 2 (CH 2 )
- Page 48 and 49: 1.4 Kinetic Interest The platinum-b
- Page 50 and 51: 3. The effect of varying the positi
- Page 52 and 53: 17 R. A. Henderson, The Mechanism o
- Page 54 and 55: Altona J. H. van Boom, G. A. van de
- Page 56 and 57: 76 (a)J. Kašpárková, J. Zehnulov
- Page 58 and 59: Table of Contents-2 Chapter Two ...
- Page 60 and 61: List of Tables Table 2.1: A selecti
- Page 62 and 63: The mononuclear Pt(II) complexes 1-
- Page 64 and 65: Potential Energy R + X RX 1 transit
- Page 66 and 67: For the associative mechanism (A),
- Page 68 and 69: the concentration of one of the rea
- Page 70 and 71: k obs , s -1 0.00030 0.00025 0.0002
- Page 72 and 73: k = Ae -Ea/RT 2.14 lnk = lnA - E a
- Page 74 and 75: = 23.76 + R Hence, a plot of ln ⎛
- Page 76 and 77: iii. # Δ V ≈ 10 cm3 mol-1 featur
- Page 78 and 79: conventional methods are classical
Figure 1.4: DNA-adduct formation with cisplatin leaving two amino groups coordinated on the<br />
platinum atom. The main adducts formed in the interaction cisplatin with DNA: (a) interstrand crosslink;<br />
(b) 1,2-intrastrand cross-link; (c) 1,3-intrastrand cross-link and; (d) protein-DNA cross-link. ..... 7<br />
Figure 1.5: Schematic pathway <strong>of</strong> a platinum drug in cells showing how sulphur containing<br />
compounds are thought to act as potential drug reserving agents in platinum chemotherapy. ............... 9<br />
Figure 1.6: DNA adducts formed by oxaliplatin 13 . ............................................................................... 11<br />
Figure 1.7: Structure <strong>of</strong> a sterically hindered platinum(<strong>II</strong>) complex (ZD0473) that circumvents<br />
cisplatin resistance. ............................................................................................................................. 12<br />
Figure 1.8: Selected Pt(<strong>II</strong>) metallo-intercalators: terpy = terpyridine, phen = phenanthroline, 4picoline<br />
= 4-methylpyridine, en = 1,2-diaminoethane, and HET = 2-hydroxyethanethiolato<br />
ligand. ................................................................................................................................................... 13<br />
Figure 1.9: Selected Multinuclear platinum(<strong>II</strong>) complexes with flexible amino- and rigid azine<br />
and azoles ligands. , .............................................................................................................................. 15<br />
Figure 1.10: Structure <strong>of</strong> extended terpy Pt(<strong>II</strong>) complexes; blue ring for isoquinoline ring and<br />
red for phenanthroline ring system. .................................................................................................. 18<br />
ii